Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider Sells $100,436.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 6,800 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $14.77, for a total value of $100,436.00. Following the transaction, the insider now owns 622,869 shares of the company's stock, valued at $9,199,775.13. This trade represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

David Krempa also recently made the following trade(s):

• On Monday, June 16th, David Krempa sold 10,223 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.73, for a total transaction of $150,584.79.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total value of $253,296.84.

Eton Pharmaceuticals Stock Up 0.7%

Eton Pharmaceuticals stock traded up $0.09 during mid-day trading on Thursday, reaching $13.70. 341,413 shares of the company were exchanged, compared to its average volume of 227,647. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97. The firm has a market cap of $367.43 million, a P/E ratio of -76.11 and a beta of 1.28. The business has a fifty day moving average of $16.63 and a 200 day moving average of $15.03. Eton Pharmaceuticals, Inc. has a 12-month low of $3.18 and a 12-month high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. The company had revenue of $17.28 million for the quarter, compared to analysts' expectations of $14.33 million. Research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ETON. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, B. Riley reissued a "buy" rating and set a $26.00 target price (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. AlphaQuest LLC bought a new stake in shares of Eton Pharmaceuticals in the 1st quarter valued at about $53,000. Tower Research Capital LLC TRC acquired a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $86,000. Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals in the first quarter worth $101,000. Jefferies Financial Group Inc. acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth $133,000. Finally, Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock valued at $141,000 after purchasing an additional 1,634 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.